Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.54 |
| ▸ | KDR | P35968 | 8/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | GOT1 | P17174 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MPO | P05164 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.49 |
| ▸ | ACOX1 | Q15067 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29178078 | 0.81 | LMNA (0.44) | EGFRKDRLMNAKDM4ETP53 | |
| SCHEMBL28867655 | 0.79 | NPC1 (0.42) | EGFRKDRLMNAKDM4ETP53 | |
| SCHEMBL169719 | 0.72 | PLAU (0.52) | LMNACYP3A4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29482553 | 0.72 | PLAU (0.52) | LMNACYP3A4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL276918 | 0.70 | LMNA (0.52) | EGFRKDRLMNAKDM4ETP53 | |
| SCHEMBL600018 | 0.70 | KDM4E (0.57) | EGFRKDRLMNAKDM4ETP53 | |
| SCHEMBL29560277 | 0.70 | KDM4E (0.57) | EGFRKDRLMNAKDM4ETP53 | |
| Hydralazine SCHEMBL8703662 | 0.69 | ALDH1A1 (0.81) | EGFRKDRLMNAKDM4ETP53 | |
| Sulfuric Acid SCHEMBL3440665 | 0.69 | ALDH1A1 (0.43) | EGFRKDRLMNAKDM4ETP53 | |
| SCHEMBL30523852 | 0.69 | KDM4E (0.55) | EGFRKDRLMNAKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113750084-A | New application of phthalazinone sulfate as NDM-1 inhibitor or antibiotic protective agent | 东北农业大学 | 2021-12-07 | — | — | CN | disclosed |
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | AMGEN INC. | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | SCN7A, SCN1A, SCN5A | EGFR 4591/4885KDR 3471/4885LMNA 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.